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Abstract Specific mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia type 2A, a hereditary syndrome characterized by tumorigenesis in multiple
glandular elements. In rare instances, MEN2A-associated germline RET mutations have also
occurred with non-MEN2A associated cancers. One such germline mutant RET mutation
occurred concomitantly in a young adult diagnosed with alveolar rhabdomyosarcoma, a pediatric and young adult soft-tissue cancer with a generally poor prognosis. Although tumor
tissue samples were initially unable to provide a viable cell culture for study, tumor tissues
were sequenced for molecular characteristics. Through a hierarchical clustering approach,
the index case sample was matched to several genetically similar cell models, which were
transformed to express the same mutant RET as the index case and used to explore potential therapeutic options for mutant RET-bearing alveolar rhabdomyosarcoma. We also determined whether the RET mutation associated with the index case caused synthetic
lethality to select clinical agents. From our investigation, we did not identify synthetic lethality associated with the expression of that patient’s RET variant, and overall we did not find
experimental evidence for the role of RET in rhabdomyosarcoma progression.
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Rhabdomyosarcoma (RMS) is the most prevalent pediatric soft tissue sarcoma, with frequent
incidence in adolescent and young adults (Rudzinski et al. 2017). The alveolar subtype (aRMS)
accounts for 20%–30% of all RMS tumors and thus represents ∼1% of all pediatric cancers.
aRMS has an annual incidence within the United States of ∼350 cases/yr (Amer et al. 2019).
aRMS is commonly initiated by a gene fusion event, most prevalently the PAX3:FOXO1-positive (P3F) variant, less commonly the PAX7:FOXO1-positive (P7F) variant, and rarely the atypical fusions (PAX3:NCOA1, PAX3:INO8) or even fusion-negative (Parham and Barr 2013;
Shern et al. 2014). A substantial fraction of patients who develop metastatic aRMS (25%–
30%) have metastatic disease at the time of diagnosis, with aRMS most frequently spreading
to bone marrow, distal nodes, and bone (Ognjanovic et al. 2009; Amer et al. 2019).
Standard clinical care for aRMS is a combination of surgery, radiation, and intensive chemotherapy (Hawkins et al. 2013). Therapeutic schedules have been developed for RMS patients based on their Oberlin risk group, with the goal of reducing therapy-related toxicity in
patients in low risk groups. The Oberlin risk score is determined by several factors but is
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strongly influenced by the number of metastatic lesions and the location of the metastatic
disease. RMS patients with fusion-positive tumors are more likely to have a higher risk score
than fusion-negative patients; however, fusion status has little additional prognostic value
when patients are stratified by Oberlin score. The 5-yr event-free survival rates based on
Oberlin score are Oberlin 0 or 1, 52.4%; Oberlin 2, 22.8%; Oberlin 3, 6.3%; and Oberlin
4, 0% (Rudzinski et al. 2017).
The research presented here complements our case report of a teenage male patient
(denoted CF-00034) with a germline RET C634F mutation diagnosed with aRMS bearing
the canonical PAX3:FOXO1 genomic rearrangement (Crawford et al. 2020). RET mutations
occur in 1.8% of tumors across disparate disease types (Kato et al. 2017), and the PAX3:
FOXO1 fusion occurs in 55% of ARMS cases (Marshall and Grosveld 2012). The RET
C634F mutation is associated with Multiple Endocrine (MEN) Type 2 and has well established oncogenic potential (Schuffenecker et al. 1998; Zhou et al. 2007; Masbi et al.
2014). Prior reports demonstrate metastatic PAX3:FOXO1 aRMS in a 13-yr-old male
(Agarwal et al. 1997; Jones et al. 2010) with familial MEN Type 2A induced by RET
V804M mutation, a patient genotypically and phenotypically reminiscent of the index patient. MEN syndromes can also be caused by loss-of-function mutations in MEN1 or
CDKN1B, such as a case of rhabdomyosarcoma with a MEN1 1280delG truncation mutation
(Alpers and Jones 2010). Nonetheless, rhabdomyosarcoma bearing MEN syndromes is a
rare occurrence with few published clinical cases.
RET is a transmembrane coreceptor tyrosine kinase involved in neurite guidance and outgrowth (Hezam et al. 2018). In neurons, RET stimulates a multitude of biological functions
including cell survival, differentiation, proliferation, and migration/chemotaxis. In cancer
cells RET is associated cell migration and proliferation, autophagy, and chemoresistance
(Mulligan 2019). RET mutations occur regularly in other cancer types such as medullary thyroid cancer (43%–71% of patients) and lung carcinosarcoma (16.7%) (Kato et al. 2017), which
has led to clinical trials of highly selective RET inhibitors with promising results (Ackermann
et al. 2019). RET signaling requires the stepwise assembly of a signaling complex that first
requires binding of a dimerized ligand of the glial cell line–derived neurotrophic factor
(GDNF) family (GDNF, neurturin [NTRN], artemin [ARTN], persephin [PSPN]) by two GDNF
family receptors (GFRα1–4) (Takahashi 2001), which forms a tetrameric complex that binds
and induces dimerization of RET (Supplemental Fig. 1A). The active signaling complex in
a 2:2:2 ratio results in trans-autophosphorylation of RET that can lead to activation of several
signaling pathways including MAPK, PI3K/AKT, and Src. However, mutant RET does not
have the same signaling complex requirements. Mutations in the kinase domain or RET rearrangements render the kinase constitutively active (Cranston et al. 2006), whereas mutations in the RET extracellular domain, as in the case of the index patient (C634F), render
the receptor ligand-independent (Kjær et al. 2006).
Given the association of mutant RET to cancer oncogenesis and metastasis, and previous
reports of mutant RET in aRMS patients (Agarwal et al. 1997; Jones et al. 2010; Crawford
et al. 2020), we investigated if the germline RET mutation coincident in a subset of aRMS patients may have contributed to the clinical course of CF-00034, and if the RET C634F mutation subsequently induces atypical susceptibilities in RMS tumor cells for patients with
elevated RET expression or germline RET mutations.

RESULTS
RET Signaling Components in aRMS
To determine the importance of RET activity in aRMS, we evaluated the survival data and
paired gene expression data from sporadic cases of RMS (n = 23 cases) archived by the
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Figure 1. RET expression versus aRMS outcome. For the Intergroup Rhabdomyosarcoma Study Group 4 clinical trial (Blandford et al. 2006), increased RET gene expression in new-diagnosis biopsy samples is associated
with the trend for reduced patient survival over a 10-yr period (P = 0.069, multivariate analysis adjusted for gender, age, stage, and fusion type for Pax:Foxo+ aRMS).

Children’s Oncology Group (Fig. 1). RET expression demonstrated a trend associated with
decreased long term survival over 10 years in an expression-dependent manner when adjusted for known clinical covariates (age, stage, sex, fusion status), although cohort sizes
were small (four to 14 patients/group) and results did not reach statistical significance (P =
0.069). We next evaluated whole-transcriptome sequencing data from human aRMS biopsy
samples to determine the expression of the RET signaling complex members (Supplemental
Fig. 1). Although RET and GFRα were expressed in several samples, no single sample expressed both coreceptors RET and GFRα simultaneously. The evaluation of this diverse collection of RMS tumors indicates that RET is rarely expressed (∼5%), whereas coreceptors
GFRA1–4 are more commonly expressed (∼34%), and all samples transcribe at least one
RET ligand, with ATRN and NRTN being near-universally expressed.
Endotype Analysis and Compound Screen of Endotypically Similar Cell Models
The lack of available RET-mutant aRMS cell models coupled with lack of patient-derived
primary cultures at the time of our studies necessitated identifying cellular models genomically and transcriptionally similar to the index case for in vitro experiments. Similarity of
cell models was quantified using an aRMS-focused dendrogram endotype computational
model (Ricker et al. 2020). Multiple aRMS exome and transcriptomes sequencing data sets
were obtained from internal cc-TDI CuRe-FAST samples, the Database of Genotypes and
Phenotypes (dbGaP), the Gene Expression Omnibus (GEO) database, Foundation
Medicine sequencing panels, the Jackson Laboratory PDX sequencing data, and
Champions Oncology PDX sequencing data as well as statistical comparison of RET and
RET signaling partner expression between ARMS and ERMS cohorts (Supplemental Tables
1, 2). Using DNA mutation data and RNA expression data from the accumulated aRMS sample
cohort, endotype clustering analysis was performed on the aRMS sample sequencing data
cohort. Hierarchical clustering identified multiple out-groups (self-clustering consistent
with expectations) such as Foundation Medicine panel data (which identifies mutations in a
subset of tumor-associated genes), non-PAX3 fusion aRMS samples, and fusion-negative
samples.
An endotype emerged which focused on RET expression as a key differentiator between
hierarchical clusters (Fig. 2A). The index case was determined to be endotypically most similar to CF-00001X (a pediatric PAX3–FOXO1 aRMS with an established PDX model and PDXderived cell line), U31431 (a PAX3–FOXO1 GEM model–derived cell culture), and four
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Figure 2. Index case endotype and patient avatar cell models. (A) Endotype dendrogram of PAX3–FOXO1
and PAX7–FOXO1 alveolar rhabdomyosarcoma patient samples, cell lines, patient-derived xenograft (PDX)
models, and genetically engineered mouse (GEM) models. Data sets were obtained from internal cc-TDI
CureFAST samples, database of genotypes and phenotypes (dbGaP) and gene expression omnibus (GEO) sequencing data, Foundation Medicine sequencing panel data, Jackson Laboratory PDX sequencing data, and
Champions Oncology PDX sequencing data. Based on DNA and RNA expression of genes in both aRMS
variants, multiple aRMS endotypes exist. Validation outgroups include Foundation Medicine samples (outgrouped because of focused sequencing of a subset of target genes) and PAX7–FOXO1 samples (outgrouped because of expected molecular differences from PAX3–FOXO1 samples). (B) Cell models identified
as endotypically most similar to the index patient CF-00034 through endotype analysis and hierarchical clustering of aRMS samples and cell models.

additional GEM cell models (U48484, U23674, U28285, U34279), all bearing PAX3–FOXO1
fusions (Fig. 2B). Lacking a CF-00034-originating cell culture, cell models identified through
endotype analysis were used as surrogates for the index case in subsequent experiments.
The human cell model (CF-00001X) and murine cell model (U31314) endotypically most
similar to index patient CF-00034 were screened in a 60-compound drug screen
(Supplemental Table 3) to identify therapeutic strategies potentially applicable to the index
case (e.g., synthetic lethality). U31314 supplemented with RET ligand ARTN (100 nM) was
assayed a second time using the 60-compound screen; no significant difference in drug sensitivity was observed.
Although CF-00001X was sensitive to a greater number of agents than U31314, few
drugs showed growth inhibition activity in both models. Of note, we observe CF-00001X
was sensitive to IGFR1 inhibitors (OSI-906 and BMS-754807), HDAC inhibitors (panobinostat, CUDC101, CUDC907 and entinostat), and inhibition of several targets in the PI3K pathway (AKT, PI3K, and mTOR).
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Phenotypic Analyses
The presence of a known, characterized oncogenic germline RET mutation (Schuffenecker
et al. 1998; Masbi et al. 2014) led to the hypothesis that clinical RET inhibitors, as monotherapy or in combination, would be promising treatment options for RET-mutant aRMS. To test
this hypothesis, we created synthetic mutant RET cell models mimicking the genotype of the
index case patient. Human and murine aRMS cells selected as representative models from
the dendrogram (Fig. 2B) were transiently transfected with commercially available RET
C634F expression plasmid and assayed with a panel of clinically available agents relevant
to aRMS biology and the germline RET mutation (Fig. 3). Transfection of cell models was confirmed by western blot analysis (Fig. 4A), confirming expression of RET C634F and expression of MYC–DDK (FLAG) tagged protein.

Figure 3. Monotherapy treatment of null plasmid and RET C634F plasmid transformed endotypically similar
cell models. Four cell models identified as endotypically similar to the index patient CF-00034 (CF-00001X,
RH30, U23674, U31431) were treated with six different monotherapies (cabozantinib, entinostat, vincristine,
cyclophosphamide prodrug, mafosfamide, temsirolimus) to determine agent response and unique sensitives
induced by RET C634F protein expression.
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Figure 4. Cabozantinib-focused drug combinations in synthetic RET-mutant cell lines. (A) Western blots of
null plasmid and RET C634F transformed endotypically similar cell models, confirming successful transformation and expression of RET C634F. The western blot image in this panel was generated from the grouping of
two individual western blot images. No other modifications were made to the western blot image. (B)
Representative 3D response manifold of RET C634F transformed RH30 cell model treated with combinations
of cabozantinib and entinostat. (C ) Representative 3D response manifold of null transformed RH30 cell model
treated with combinations of cabozantinib and entinostat. (D) Representative Chou–Talalay Combination
Index values from RET C634F cabozantinib plus entinostat combination. (E) Representative Chou–Talalay
Combination Index values from null plasmid cabozantinib plus entinostat combination.

The clinical RET inhibitor cabozantinib was selected as the experimental RET inhibitor
because of off-label clinical use in the previous case report (Crawford et al. 2020).
Cabozantinib has been investigated clinically for RET-rearranged non-small-cell lung cancer
(Drilon et al. 2016) and has shown significant clinical efficacy in RET M918T mutant medullary
thyroid cancer (Krajewska et al. 2016). For combination therapies, we selected two clinical
chemotherapy agents (vincristine and cyclophosphamide [tested as the prodrug mafosfamide]) not used to treat the index case patient described in the preceding manuscript
(Crawford et al. 2020) and two clinical targeted inhibitor compounds (HDAC inhibitor entinostat [recently in a Phase I pediatric clinical trial, ADVL1513/NCT02780804] and mTOR
inhibitor temsirolimus). Each agent was first tested as a monotherapy to determine overall
single agent efficacy across RET C634F transfected and null plasmid cell models (Fig. 3).
Drug response to monotherapy and cabozantinib-focused combination therapy of RET
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Table 1. Statistical analysis of monotherapy and combination drug screens with and without synthetic RET
mutation
IC50 value comparison (P-value)
Human

Cabozantinib
Entinostat
Vincristine
Mafosfamide

Mouse

RH30

CF1X

U23674

-

-

1 × 10−04

-

1 × 10−04

1 × 10−04

0.7298

1 × 10

−04

U31431

-

-

0.0719

-

0.9604

0.7746

-

-

Statistical comparison of RET WT and RET C634F monotherapy IC50 values. Comparison is provided as P-values, with
green text indicating statistically significant differences.

C634F transfected versus null plasmid transfected cell models were tested for statistically
significant differences. For monotherapy, absolute IC50 values were used for statistical
comparison when available or dose-level response vectors were used when single agents
did not achieve 50% growth inhibition. In RET C634F transfected versus null cell models,
no monotherapy treatment showed statistically significant change in sensitivity across all
cell models (Fig. 3).
Combination therapies were tested in checkboard dosage design, with cabozantinib
tested in combination with the remaining five monotherapy agents. Combination Index values and 3D dose response manifolds were generated for each cell model/drug combination
(representative manifold presented in Fig. 4B,C). Several combinations exhibited synergy at
specific combination doses and/or at dose regions in RET C634F synthetic cell models (representative combination index plots are presented in Fig. 4D,E). All manifold and combination index results are provided in Supplemental Table 4.
We also tested for statistically significant differences in single agent response based on
IC50 values (Table 1) and overall response curve (Table 2), as well as differences in drug combination response manifolds in RET C634F transfected versus null cell models (Table 3).
Although no monotherapy or combination therapy showed statistically significant change
across all cell models, monotherapy entinostat showed statistically significant difference in
three of four models. However, although the statistically significant human model (RH30)
showed increased sensitivity to entinostat, both mouse models showed statistically decreased entinostat sensitivity. Additionally, both RH30 and U31431 show statistically

Table 2. Statistical analysis of monotherapy and combination drug screens with and without synthetic RET
mutation
Monotherapy response vector comparison (P-value)
Human
RH30

Mouse
CF1X

U23674

U31431

Cabozantinib

0.37

0.7706

0.5068

0.1772

Entinostat

0.1363

0.0215

0.0681

0.1375

Vincristine

0.0512

0.5773

0.0136

0.5747

Mafosfamide

0.0604

0.3234

0.3652

0.1196

Statistical comparison of RET WT and RET C634F monotherapy response vectors. Comparison is provided as P-values,
with green text indicating statistically significant differences.
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Table 3. Statistical analysis of monotherapy and combination drug screens with and without synthetic RET
mutation
Combination therapy response vector comparison (P-value)
Human
RH30

Mouse
CF1X

U23674

U31431

cab-ent

0.8663

0.529

0.0252

0.7756

cab-vnc

0.1905

0.1199

0.4231

0.1532

cab-maf

0.0062

0.1105

0.3825

0.0319

Statistical comparison of RET WT and RET C634F combination therapy response vectors as P-values. Comparison is
provided as P-values, with green text indicating statistically significant differences.

significantly different response to the cabozantinib + mafosfamide combination, as well as
increased overall synergy by combination index values (Supplemental Table 4).
Nonetheless, the overall lack of statistically significant differences between RET C634F transfected versus null plasmid cell models across all models suggests RET C634F mutation in
rhabdomyosarcoma may not induce sensitivity to RET inhibition, nor confer additional sensitivity to chemotherapy agents or targeted agents.

DISCUSSION
This research began with an unusual clinical observation, an aRMS patient with aggressive
metastatic disease has an underlying germline RET C634F-activating mutation. RET activation is known to be the ligand-independent, self-activated driver mutation of MEN2A syndrome cancers and thought to be involved in lung adenocarcinoma (Wang et al. 2019),
breast cancer (Paratala et al. 2018), non-small-cell lung cancer, and colorectal cancer
(Gozgit et al. 2018). Given the unique genotype of the patient. the poor prognosis associated with metastatic aRMS, and previous success of RET inhibitors in RET mutant tumors
(Ackermann et al. 2019), we investigated the lethality of a clinical RET inhibitor as a monotherapy or in combination with other clinically available agents when treating RET-mutant expressing cell models. Sensitivity to monotherapies and combination therapies were
consistent in both null plasmid transformed and RET C634F transformed cell models, suggesting the RET mutation borne by the patient did not induce new susceptibility to RET inhibition. Although RET mutation does not necessarily guarantee complete response to a RET
inhibitor (Valenciaga et al. 2018), lack of any significant susceptibility to RET inhibition is surprising and speaks to the clinical challenge aRMS presents even when a genomically relevant
target is readily druggable.
Promisingly, the recently U.S. Federal Drug Administration (FDA)-approved RET inhibitor
selpercatinib has been approved for the use in RET fusion-positive non-small-cell lung cancer (Drilon et al. 2020) and medullary thyroid cancer with RET mutations or RET fusions (Wirth
et al. 2020), including both kinase-domain mutations and extracellular cysteine mutations.
Notably, extracellular cysteine mutations show overall reduced response to selpercatinib
compared to kinase domain mutations. Given the use of cabozantinib as a maintenance therapy in the index case patient, the potential impact of selpercatinib in the index case or similar
patients is unclear.
We also tested a panel of multiple agents relevant to rhabdomyosarcoma biology
against two of the endotype-based cell models, identifying susceptibility to IGFR1 and
PI3K inhibitors in the endotypically closest human cell model, consistent with previous
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aRMS studies (Crosswell et al. 2006; Abraham et al. 2011; Berlow et al. 2019), again supporting RET status playing a minimal role in altering response to therapeutic agents. Although
rarely occurring concomitantly, metastatic aRMS with RET C634F germline mutation presents a difficult phenotype and a dire clinical prognosis and will likely remain as intractable
as classical aRMS cases.
A key challenge in the investigation of RET C634F mutant aRMS is the lack of readily available cell models and the initial biopsy material from the patient not generating a viable cell
culture. Overcoming the lack of patient-derived cell model by using a cohort of sequenced
aRMS samples to identify available cell models most molecularly similar to the index case is a
strategy for research-level functional analysis, which may be applicable to other patients with
atypical or challenging genotypes. Development of rare disease cohorts will beneficial both
in understanding the disease as a whole but also in exploring the unique genotypes possessed by individual patients.

METHODS
Cell Lines
The RH30 cell line (Douglass et al. 1987) (RRID:CVCL_0041) was shared by the Children’s
Oncology Group Repository (https://www.cccells.org/). RH30 was cultured in RPMI-1640
(11875-093; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS)
(26140079; Thermo Fisher Scientific) plus 1% penicillin-streptomycin (P/S) (15140-122;
Thermo Fisher Scientific) maintained at 5% CO2 at 37°C.

Murine Cell Model Establishment
The mouse primary tumor cell cultures U31431 and U23674 were established from a site-oforigin conditionally induced aRMS tumor in a genetically engineered Myf6Cre,Pax3:Foxo1,
p53 mouse as previously described (Abraham et al. 2014). In brief, extracted tumor was
minced and digested with 10 mg/mL collagenase type IV (17104019; Thermo Fisher
Scientific) overnight at 4°C. Dissociated cells were then incubated in Dulbecco’s modified
Eagle’s medium (DMEM) (11995-073; Thermo Fisher Scientific) supplemented with 10%
FBS and 1% P/S in 5% CO2 at 37°C. Cultures were maintained at low passage to minimize
biological variation from the original tumor. All experiments were performed at or below passage 10.

Patient-Derived Xenograft (PDX) Model Development
All aspects of cancer tissue sharing for model development were reviewed and approved by
the Children’s Cancer Therapy Development Institute Institutional Review Board. The CF00001 PDX model and subsequent cell culture (denoted CF-00001X) were described previously (Bharathy et al. 2018). Fusion status of CF-00001 PDX-derived cells (denoted CF00001X) was confirmed by RNA sequencing for PAX3–FOXO1 fusion reads and western
blotting of CF-00001X culture lysate for PAX3–FOXO1 (Bharathy et al. 2018). Cultures
were maintained at low passage to minimize biological variation from the original tumor.
All experiments were performed at or below passage 10. CF-00001X was cultured in
RPMI-1640 supplemented with 10% fetal bovine serum (FBS) plus 1% P/S and maintained
at 5% CO2 at 37°C. The CF-0001 PDX model is maintained at the Jackson Laboratory
(http://tumor.informatics.jax.org/mtbwi/pdxDetails.do?modelID=J000099761).
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Data Integration and Dendrogram Generation
To define endotypes (disease subgroups defined by combined genomic, clinical, and pathobiological feature sets unique to each patient) within aRMS, we applied hierarchical agglomerative clustering analysis to a cohort of aRMS samples including human patient
samples with PAX3–FOXO1 fusions (n = 23), patient samples with PAX7–FOXO1 fusions (n
= 6 samples), patient samples with PAX3–NCOA1 fusions (n = 2 samples), patient samples
with PAX3–INO8 fusions (n = 1 sample), fusion-negative patient samples (n = 8), patient-derived aRMS cell lines (n = 12), Foundation Medicine panel sequencing result from human
aRMS (n = 15), genetically engineered mouse models (n = 17), and PDX models of human
aRMS from Champions Oncology (n = 2: CTG-0329 and CTG-1419) and the Jackson
Laboratory (n = 4: CF1_00327, CF2_06843, CF4_01466, PCB380_03416).
Data from disparate human data sets were aligned to a common set of genes across DNA
sequencing data and RNA sequencing data. Mouse-origin samples were converted from
mouse gene identifiers to homologous human gene identifiers via BioMart (Smedley et al.
2009) and merged with the human DNA or RNA sequencing data sets, respectively. Gene
expression values were normalized to read depth across samples using edgeR (Robinson
et al. 2009) and then across individual genes by assigning gene-level z-scores. Zero expression values were assigned to all DNA sequencing data sets lacking RNA sequencing data
(i.e., Foundation panel sequencing data sets) to allow for clustering analysis. For mutation
data, samples were assigned the value 1 for each gene bearing a mutation, and 0 otherwise.
The resulting quantified mutation and expression data sets were concatenated as feature
vectors for downstream clustering analysis. The Euclidean distance metric was used to define
distance between feature vectors, with average-linkage clustering used to merge nonsingleton feature vectors into groups. Clustering analysis was performed using RStudio Version
3.6.1 using the hdist package.
Sequencing Data Analysis
All sequencing data from patient samples, patient-derived cell lines, genetically engineered
mouse models, and the Jackson Laboratory PDX models were analyzed by the previously
published analysis pipeline (Kats et al. 2019). In brief, gene mutations from whole-exome sequencing experiments were identified by aligning fastq files to the GRCh38 human reference genome or GRCm38 mouse reference genome via BWA aligner, processing with
GATK best practices (DePristo et al. 2011), and called with MuTect2 (Benjamin et al.
2019). Gene expression from whole transcriptome sequencing experiments was analyzed
by aligning fastq files to the GRCh38 human reference genome or GRCm38 mouse reference
genome using STAR aligner (Dobin et al. 2013) and quantified by RSEM (Li and Dewey 2011).
Drug Screen of Endotypically Similar Cell Models
CF-00001X and U31431, were evaluated in a proliferation assay against a 60-compound library which was previously described and reported (Kats et al. 2019). In brief, cells were cultured and harvested, then plated via BioTek MultiFlo liquid dispenser into thawed
preprinted compound library 384-well opaque white wall plates (164610; Thermo Fisher
Scientific). Cells in plates were incubated for 72 h then assayed for cell viability via
CellTiter Glo 2.0 (G9241; Promega) luminescent assay. Drug response and IC50 values
were determined using Microsoft Excel.
Transfection of PAX3–FOXO1 Alveolar Rhabdomyosarcoma Cell Models
The RET mutant plasmid RET C634F built into pCMV6 Entry. carboxy-terminal Myc/DDK
FLAG Tagged cloning vector was purchased from OriGene (RC403308; OriGene) and
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expanded by Aldevron (http://www.aldevron.com/). The plasmid was transfected into four
cell models: RH30, CF-00001X, U23674, and U31431.
Cells were plated in tissue-culture treated six well plates (140675; Thermo Fisher
Scientific) at initial cell populations at 150,000 cells/well. After a 24-h acclimation period,
the plated cells were transfected with DNA plasmid (lipofectamine 6 µL + 2 µg DNA) for
2 h in serum-free media (RPMI-1640 for human cells, DMEM for murine cells), and then
washed and replaced with growth media. Transient transfection of RET C634F plasmid via
the above methodology was confirmed for all cell models via western blot for Myc/DDK
FLAG antibody (F3165; Millipore Sigma).
Immunoblotting
Following transfection, all four cell models were cultured for 24 h then harvested for protein
via RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific 89900) + Halt Protease and
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific 78441). Null plasmid cells were cultured for 48 h, and protein was isolated in the same manner. RET expression in transfected
and null plasmid cell models was analyzed using ant-RET antibody (1:1000 dilution; Cell
Signaling Technologies 3220). Presence of RET C634F protein was confirmed using antiFLAG M2 antibody (1:5000 dilution; Sigma-Aldrich F1804).
Monotherapy and Combination Therapy Drug Studies of Transformed Cell Models
Cell lines transfected with either null pCMV6 Entry plasmid or RET C634F pCMV6 Entry plasmid were collected and plated in growth media at 1500 cells/well into 384-well drug plates
preprinted with six agents validated as a monotherapy and five cabozantinib-focused drug
combinations based on the six monotherapy agents. The following drugs were tested as
monotherapy: cabozantinib (Selleck Chemicals S4001), entinostat (Selleck Chemicals
S1053), vincristine (Selleck Chemicals S1241), mafosfamide (Santa Cruz Biotechnology
sc-211761), and temsirolimus (Selleck Chemicals S1044). Individual agents were tested in
triplicate at the following doses: [10 nM, 100 nM, 1 µM, 10 µM]. The following two-drug
combinations were selected for validation: cabozantinib + entinostat, cabozantinib + vincristine, cabozantinib + mafosfamide, and cabozantinib + temsirolimus. Each combination of
agents was tested at the Cartesian product of the following dosages: cabozantinib [10
nM, 100 nM, 1 µM, 10 µM] × combination agent [10 nM, 100 nM, 1 µM, 10 µM] for a total
of 16 data points per combination. Three technical replicates of each monotherapy/combination screen were performed for each null plasmid– and RET C634F plasmid–transfected
cell model. Cell models in growth media were plated in the preprinted plates and incubated
for 72 h in 5% CO2 at 37°C. At the end of the 72-h period, cell viability was assessed by
CellTiter Glo 2.0 luminescent assay per manufacturer’s protocol and quantified via BioTek
Synergy HT plate reader.
Drug sensitivity as IC50 value of each monotherapy was determined by Hill curve fitting
using GraphPad Prism. Chou–Talalay Combination Index values (Chou 2010) for drug combinations were generated using the CompuSyn software tool. Effect values for CompuSyn
monotherapy and combination therapy were determined by mean cell viability based on
n = 3 independent technical replicates for each transfected cell model. Each null plasmid–
and RET C634F plasmid–transfected cell model was compared for statistically significant differences of drug response to determine if RET C634F expression resulted in changes in drug
sensitivity.
Sequencing Data
Sequencing data for endotype analysis and dendrogram generation were gathered from previously published data sets with the following accession IDs: GSE138269, GSM984615,
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GSM758578, GSE142775 (Gene Expression Omnibus database), EGAS00001004359,
EGAS00001003981 (European Genome-phenome Archive), PRJNA613152 (Short Read
Archive), Champions TumorGraft database, Mouse Tumor Biology Database (http://tumor
.informatics.jax.org/mtbwi/pdxSearch.do), the OncoGenomics Database (https://pob.abcc
.ncifcrf.gov/cgi-bin/JK), and phs001121.v1.p1 (Database of Phenotypes and Genotypes).
Statistics
Student’s t-tests were used to compare IC50 values from null and RET C634F transfected
aRMS cell lines treated with different monotherapy agents. Hotelling’s T 2 test was used to
compare one-dimensional drug response vectors from null and RET C634F transfected
aRMS cell lines treated with different monotherapy agents, when 50% inhibitory concentrations were not reached. Hotelling’s T 2 test was also used to compare two-dimensional drug
response manifolds from null and RET C634F transfected aRMS cell lines treated with different combination therapy agents.
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Omnibus database), EGAS00001004359, EGAS00001003981 (European Genome-phenome Archive), PRJNA613152 (Short Read Archive), Champions TumorGraft database,
Mouse Tumor Biology Database (http://tumor.informatics.jax.org/mtbwi/pdxSearch.do),
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